| AERIE PHARMACEUTICALS INC |
|---------------------------|
| Form SC 13G/A             |
| February 04, 2019         |

| UNITED STATES   |
|---|
| SECURITIES AND EXCHANGE COMMISSION                      |
| Washington, D.C. 20549                                  |
|   |
| SCHEDULE 13G  |
| (Rule 13d-102)  |
|   |
| Information Statement Pursuant to Rules 13d-1 and 13d-2 |
| Under the Securities Exchange Act of 1934               |
| (Amendment No. 2)*                                      |
|   |
| Aerie Pharmaceuticals, Inc.                             |
|   |
| (Name of Issuer)  |
|   |
| Common stock, par value \$0.001 per share               |
| (Title of Class of Securities)                          |
| (   |
| 00771V108   |
|   |
| (CUSIP Number)  |

| December 31, 2018  |
|--|
| Date of Event Which Requires Filing of the Statement   |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed:  |
| "Rule 13d-1(b) xRule 13d-1(c) "Rule 13d-1(d)   |
| *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.  |
| The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). |
|  |

```
Cusip No. 00771V108 13G/A Page 2 of 13 Pages
```

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1.
 Partner Fund Management, L.P.
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)
2.
 (b)
       X
 SEC USE ONLY
3.
 CITIZENSHIP OR PLACE OF ORGANIZATION
4.
 Delaware
               SOLE VOTING POWER
             5.
NUMBER OF
SHARES
               SHARED VOTING POWER
BENEFICIALLY
             6.
OWNED BY
               1,893,935 shares
EACH
```

7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 0

WITH

8. SHARED DISPOSITIVE POWER

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  $_{\rm 9.}$ 

See Row 6 above

 $10. \frac{\text{CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES}}{\text{CERTAIN SHARES}}$ 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

 $4.2\%^{1}_{-}$ 

TYPE OF REPORTING PERSON

12.

IA; PN

The percentages reported in this Schedule 13G/A are based upon 45,453,615 shares of common stock outstanding as 1 of October 31, 2018 according to the Form 10-Q filed by the issuer with the Securities and Exchange Commission on November 7, 2018.

```
Cusip No. 00771V108 13G/A Page 3 of 13 Pages
```

```
NAME OF REPORTING PERSON
```

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON 1.

### Partner Fund Management GP, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

- (a) " 2.

(b)

SEC USE ONLY

X

3.

### 4. CITIZENSHIP OR PLACE OF ORGANIZATION

### **Delaware**

SOLE VOTING POWER

5.

NUMBER OF 0

**SHARES** 

SHARED VOTING POWER

**BENEFICIALLY** 

6.

OWNED BY

1,893,935 shares

**EACH** 

REPORTING 7. SOLE DISPOSITIVE POWER

PERSON 0
WITH

8. SHARED DISPOSITIVE POWER

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
9. REPORTING PERSON

See Row 6 above

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

4.2%

TYPE OF REPORTING PERSON

12.

00

```
Cusip No. 00771V108 13G/A Page 4 of 13 Pages
 NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1.
 Partner Investment Management, L.P.
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)
2.
 (b)
       X
 SEC USE ONLY
3.
 CITIZENSHIP OR PLACE OF ORGANIZATION
4.
 Delaware
               SOLE VOTING POWER
             5.
NUMBER OF
SHARES
               SHARED VOTING POWER
BENEFICIALLY
             6.
OWNED BY
```

22,559 shares

7. SOLE DISPOSITIVE POWER

**EACH** 

REPORTING

Edgar Filing: AERIE PHARMACEUTICALS INC - Form SC 13G/A
PERSON 0
WITH

8. SHARED DISPOSITIVE POWER

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
9. REPORTING PERSON

See Row 6 above

...

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

Less than 0.1%

TYPE OF REPORTING PERSON

12.

IA; PN

```
Cusip No. 00771V108 \, 13G/A Page 5 of 13 Pages
```

```
NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.
```

### Partner Investment Management GP, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) " 2.

(b) x

SEC USE ONLY 3.

CITIZENSHIP OR PLACE OF ORGANIZATION 4.

Delaware

SOLE VOTING POWER 5.

NUMBER OF 0

**SHARES** 

SHARED VOTING POWER

BENEFICIALLY

6.

OWNED BY

22,559 shares

**EACH** 

REPORTING 7. SOLE DISPOSITIVE POWER

Edgar Filing: AERIE PHARMACEUTICALS INC - Form SC 13G/A
PERSON 0
WITH

8. SHARED DISPOSITIVE POWER

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON

See Row 6 above

...

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

Less than 0.1%

TYPE OF REPORTING PERSON

12.

00

```
Cusip No. 00771V108 13G/A Page 6 of 13 Pages
```

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1.
 Brian D. Grossman
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)
2.
 (b)
      X
 SEC USE ONLY
3.
 CITIZENSHIP OR PLACE OF ORGANIZATION
4.
 U.S. Citizen
               SOLE VOTING POWER
             5.
NUMBER OF
SHARES
               SHARED VOTING POWER
BENEFICIALLY
             6.
OWNED BY
               1,916,494 shares
EACH
```

7. SOLE DISPOSITIVE POWER

REPORTING

Edgar Filing: AERIE PHARMACEUTICALS INC - Form SC 13G/A
PERSON 0
WITH

8. SHARED DISPOSITIVE POWER

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
9. REPORTING PERSON

See Row 6 above

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

4.2%

12. TYPE OF REPORTING PERSON

IN

```
Cusip No. 00771V108 13G/A Page 7 of 13 Pages
```

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1.
 Christopher M. James
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)
2.
 (b)
      X
 SEC USE ONLY
3.
 CITIZENSHIP OR PLACE OF ORGANIZATION
4.
 U.S. Citizen
               SOLE VOTING POWER
             5.
NUMBER OF
SHARES
               SHARED VOTING POWER
BENEFICIALLY
             6.
OWNED BY
               1,916,494 shares
EACH
```

7. SOLE DISPOSITIVE POWER

REPORTING

Edgar Filing: AERIE PHARMACEUTICALS INC - Form SC 13G/A
PERSON 0
WITH

8. SHARED DISPOSITIVE POWER

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
9. REPORTING PERSON

See Row 6 above

...

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

4.2%

TYPE OF REPORTING PERSON

12.

IN

Cusip No. 00771V108 **13G/A** Page 8 of 13 Pages

# **Item** Name of Issuer

Aerie Pharmaceuticals, Inc.

## Item Address of Issuer's Principal Executive Offices

2030 Main Street, Suite 1500, Irvine, California 92614

### Item Name of Person Filing 2(a)

This Schedule 13G/A is being jointly filed by Partner Fund Management, L.P. ("PFM"), Partner Fund Management GP, LLC ("PFM-GP"), Partner Investment Management, L.P. ("PIM"), Partner Investment Management GP, LLC ("PIM-GP"), Brian D. Grossman ("Grossman") and Christopher M. James ("James" and, collectively with PFM, PFM-GP, PIM, PIM-GP and Grossman, the "Reporting Persons") with respect to shares of common stock of the above-named issuer owned by PFM Healthcare Emerging Growth Master Fund, L.P., a Cayman Islands limited partnership ("HEGM"), PFM Global Long Alpha Master Fund, L.P., a Cayman Islands limited partnership ("GLAM"), PFM Global Long Alpha Institutional Master Fund, L.P., a Cayman Islands limited partnership ("GLAI"), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("HCM"), PFM Healthcare Long Master Fund, L.P., a Cayman Islands limited partnership ("HCLM"), PFM Thematic Growth Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Thematic Growth Institutional Master Fund, L.P., a Cayman Islands limited partnership ("TGI"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TM"), PFM Healthcare Principals Fund, L.P., a Delaware limited partnership ("HCP"), and PFM Thematic Growth Principals Fund, L.P., a Delaware limited partnership ("TGP" and, collectively with HEGM, GLAM, GLAI, HCM, HCLM, TGM, TGI, TM and HCP, the "Funds").

PFM is the investment advisor for the Funds other than HCP and TGP. PIM is the investment advisor for HCP and TGP. PFM-GP and PIM-GP are, respectively, the general partners of PFM and PIM. Grossman is the portfolio manager for the health care strategy for the Funds. James is the portfolio manager for the diversified strategy for the Funds. Grossman and James are co-managing members of PFM-GP and PIM-GP.

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

# Item 2(k) Address of Principal Business Office

The address of the principal business office of each of the Reporting Persons is c/o Partner Fund Management, L.P., 4 Embarcadero Center, Suite 3500, San Francisco, CA 94111.

### Item Citizenship **2**(c)

Each of PFM and PIM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PIM-GP is organized as a limited liability company under the laws of the State of Delaware. Each of Grossman and James is a U.S. citizen.

| Cusip No. 00771V108 <b>13G/A</b> Page 9 of 13 F | Pages |
|---|-------|
|---|-------|

### Item 2(d) Title of Class of Securities

Common stock, \$0.001 par value

### Item 2(e) CUSIP Number

00771V108

# Item $3\frac{\text{If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:$

- (a) "Broker or dealer registered under Section 15 of the Exchange Act;
- (b) "Bank as defined in Section 3(a)(6) of the Exchange Act;
- (c) "Insurance company as defined in Section 3(a)(19) of the Exchange Act;
- (d) Investment company registered under Section 8 of the Investment Company Act;
- (e) "An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) "An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g)" A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) "A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) "A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) "A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
- (k) "Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

17

Cusip No. 00771V108 13G/A Page 10 of 13 Pages

### **Item 4 Ownership**

- A. Partner Fund Management, L.P. and Partner Fund Management GP, LLC
- (a) PFM and PFM-GP may be deemed to beneficially own 1,893,935 shares of Common Stock.
- (b) The number of shares PFM and PFM-GP may be deemed to beneficially own constitutes approximately 4.2% of the Common Stock outstanding.
- (c) Number of shares as to which such person has:
- (i) sole power to vote or to direct the vote: 0
- (ii) shared power to vote or to direct the vote: 1,893,935
- (iii) sole power to dispose or to direct the disposition of: 0
- (iv) shared power to dispose or to direct the disposition of: 1,893,935
- B. Partner Investment Management, L.P. and Partner Investment Management GP, LLC
- (a) PIM and PIM-GP may be deemed to beneficially own 22,559 shares of Common Stock.
- The number of shares PIM and PIM-GP may be deemed to beneficially own constitutes less than 0.1% of the Common Stock outstanding.
- (c) Number of shares as to which such person has:
- (i) sole power to vote or to direct the vote: 0
- (ii) shared power to vote or to direct the vote: 22,559
- (iii) sole power to dispose or to direct the disposition of: 0
- (iv) shared power to dispose or to direct the disposition of: 22,559

Cusip No. 00771V108 **13G/A** Page 11 of 13 Pages

### C. Brian D. Grossman

- (a) Grossman may be deemed to beneficially own 1,916,494 shares of Common Stock.
- (b) The number of shares Grossman may be deemed to beneficially own constitutes approximately 4.2% of the Common Stock outstanding.
- (c) Number of shares as to which such person has:
- (i) sole power to vote or to direct the vote: 0
- (ii) shared power to vote or to direct the vote: 1,916,494
- (iii) sole power to dispose or to direct the disposition of: 0
- (iv) shared power to dispose or to direct the disposition of: 1,916,494
- D. Christopher M. James
- (a) James may be deemed to beneficially own 1,916,494 shares of Common Stock.
- $\begin{tabular}{l} The number of shares James may be deemed to beneficially own constitutes approximately 4.2\% of the Common Stock outstanding. \end{tabular}$
- (c) Number of shares as to which such person has:
- (i) sole power to vote or to direct the vote: 0
- (ii) shared power to vote or to direct the vote: 1,916,494
- (iii) sole power to dispose or to direct the disposition of: 0
- (iv) shared power to dispose or to direct the disposition of: 1,916,494

### Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

#### Item

**M** Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the

7 Parent Holding Company

See Item 2 above

#### Item

<sup>1</sup> Identification and Classification of Members of the Group

Not Applicable

Cusip No. 00771V108 **13G/A** Page 12 of 13 Pages

### **Item 9 Notice of Dissolution of Group**

Not Applicable

### Certification

Item

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Cusip No. 00771V108 **13G/A** Page 13 of 13 Pages

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated this 4th day of February, 2019.

### PARTNER FUND MANAGEMENT, L.P.

# PARTNER FUND MANAGEMENT GP, LLC

By: Partner Fund Management GP, LLC

its general partner

By:/s/ Darin Sadow

Darin Sadow, Authorized Signatory

By:/s/ Darin Sadow

Darin Sadow, Authorized Signatory

# PARTNER INVESTMENT MANAGEMENT, L.P.

PARTNER INVESTMENT MANAGEMENT GP, LLC

By: Partner Investment Management GP, LLC, By:/s/ Darin Sadow

its general partner

By:/s/ Darin Sadow
Darin Sadow, Authorized Signatory

By:/s/ Darin Sadow

Darin Sadow, Authorized Signatory

### **BRIAN D. GROSSMAN**

### **CHRISTOPHER M. JAMES**

By:/s/ Darin Sadow

Darin Sadow, attorney-in-fact\*

By:/s/ Darin Sadow
Darin Sadow, attorney-in-fact\*\*

Darin Sadow is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated \*August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.

Darin Sadow is signing on behalf of Christopher M. James as attorney-in-fact pursuant to a power of attorney dated \*\*August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.